{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-22-000030","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2022-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.337167+00:00","generated_at":"2026-06-26T12:30:24.792108+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nautilus Biotechnology appoints Karen Akinsanya, Schrödinger President, to Board","bullets":["Appointment effective March 30, 2022; Akinsanya will serve as Class III director through 2024.","Akinsanya is President of R&D, Therapeutics at Schrödinger and has 25+ years in drug discovery.","Director compensation: $40,000/year plus initial option award of 105,998 shares ($370K grant date FV).","She joins a board that includes leaders from genomics, cancer therapeutics, and tech (Illumina, Perceptive Advisors, etc.)."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-22-000030","json":"https://secwatch.observer/filing/0001808805-22-000030.json","markdown":"https://secwatch.observer/filing/0001808805-22-000030.md","text":"https://secwatch.observer/filing/0001808805-22-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000030/0001808805-22-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000030/naut-20220330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T12:30:24.792108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa488cfb4d","claim":"Karen Akinsanya was appointed as Director at Nautilus Biotechnology, Inc..","evidence_excerpt":"On March 30, 2022 , the board of directors (the “Board”) of Nautilus Biotechnology, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, appointed Karen Akinsanya to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000030/0001808805-22-000030-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}